More on RLMD

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (5.0 Score)

Upcoming Events

- Earnings (5/7/26 *Est.)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Relmada Therapeutics (NQ:RLMD)
Delayed: 4.45 +0.02 (0.45%)
Prev. Close $4.43  
Open$4.40 
52 Wk High$4.10 
52 Wk Low$0.87 
Day High$4.70 
Day Low$4.37 
P/E N/A  
EPS$0.00 
Volume450,016 

Friends, Peers and Foes (?): ABL, ABM, ASTE, BHE, BZH (more...)

Mar 2, 2026 06:05 AM Lucid Capital Markets Starts Relmada Therapeutics Inc (RLMD) at Buy
Feb 17, 2026 12:19 PM Form SCHEDULE 13G/A RELMADA THERAPEUTICS, Filed by: Squadron Capital Management LLC
Feb 17, 2026 09:16 AM Form SCHEDULE 13G RELMADA THERAPEUTICS, Filed by: Spruce Street Capital LP
Feb 12, 2026 09:13 AM Form SCHEDULE 13G RELMADA THERAPEUTICS, Filed by: Adage Capital Management, L.P.
Feb 6, 2026 04:32 PM Form SCHEDULE 13G RELMADA THERAPEUTICS, Filed by: JANUS HENDERSON GROUP PLC
Jan 30, 2026 05:14 PM Form 424B5 RELMADA THERAPEUTICS,
Jan 23, 2026 06:06 AM Leerink Partners Upgrades Relmada Therapeutics Inc (RLMD) to Outperform
Jan 12, 2026 07:02 AM Relmada gets FDA alignment on NDV-01 bladder cancer trial designs
Jan 12, 2026 07:01 AM Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications
Dec 23, 2025 10:00 AM Why Jefferies sees these stocks as standout biotech plays in 2026
View All Articles

Entities mentioned with RLMD

View All Entities